,0,1
0,wall street journal,9.0
1,insolvency liquidation bankruptcy,9.0
2,undue reliance,9.0
3,measles tetanus,9.0
4,foreign object,9.0
5,treasury yield curve,9.0
6,vertically integrated biopharmaceutical,9.0
7,app serial,9.0
8,revision,8.777777777777779
9,utility insurance travel,8.777777777777779
10,representation warranty,8.692307692307693
11,physician specialist,8.583333333333334
12,significant setback,8.548387096774194
13,baseline serum sample,8.5
14,human plasma,8.427591463414634
15,human plasma,8.427591463414634
16,immune globulin,8.408244680851064
17,security holder,8.391304347826086
18,significant improvement,8.381720430107528
19,proprietary microneutralization,8.333333333333334
20,source plasma,8.330551989730424
21,florida,8.291666666666668
22,months,8.286377829820452
23,arm study,8.266666666666666
24,diminished liquidity,8.25
25,executive officer,8.2
26,immune globulin,8.189494680851064
27,incurring indebtedness engaging,8.173913043478262
28,immune system,8.15130023640662
29,human resource,8.144886363636363
30,months,8.13073310001842
31,collaboration opportunity,8.125
32,clinical trial,8.114317425083241
33,trial enrollment,8.114317425083241
34,clinical trial,8.114317425083241
35,rata percentage,8.10344827586207
36,bank,8.1
37,validation testing,8.094927536231884
38,month,8.084790528233151
39,confidential disclosure,8.020408163265305
40,bacterial infections,8.0
41,clinical stage,7.987890735004225
42,adma biologics,7.97991452991453
43,leasehold improvement loan,7.979797979797981
44,investing activity,7.975415282392027
45,hold certification,7.965753424657534
46,additional plasma,7.924912891986063
47,clinical trial,7.91431742508324
48,material plasma,7.91049240681086
49,advisory council,7.903225806451613
50,accounting policy,7.885416666666666
51,month,7.881149071650518
52,plasma collection,7.869745718733784
53,dilutive security,7.867494824016563
54,public offering,7.830510992275698
55,capital outlay,7.825099170573386
56,donor plasma,7.824912891986063
57,ivig product,7.8202614379084965
58,shelf registration statement,7.7831066571224055
59,business combinations,7.777777777777778
60,lived asset,7.777777777777778
61,estimation process,7.771428571428571
62,fractionation,7.7714285714285705
63,regulatory approval,7.765988372093023
64,personnel protection,7.758403361344538
65,cash flow segments,7.757909704941344
66,investment distribution,7.752777777777777
67,party contractor capability,7.732142857142858
68,month,7.725504341848485
69,syncytical virus,7.719298245614034
70,staff accounting bulletins,7.71875
71,period,7.71455525606469
72,innovation dependence,7.714285714285714
73,warning letter,7.712301587301588
74,ri wa submitted,7.698412698412698
75,inspection issue,7.682142857142857
76,drug product pharmaceutical,7.681372549019608
77,potentially significantly reduce,7.679347826086957
78,patient samples,7.677083333333333
79,year beginning,7.674059274059273
80,globulin product,7.672950563204005
81,unattractive term,7.671273291925466
82,resource difficulty,7.66994266994267
83,harbor provision,7.666666666666667
84,humoral immunodeficiency,7.6571428571428575
85,intercompany transaction,7.64594807238395
86,sk representing approximately,7.631642512077295
87,common stock,7.629844497607655
88,collectability criterion presentation,7.615384615384615
89,balance sheet arrangements,7.613605442176871
90,wa,7.61304945054945
91,based compensation,7.609061214324372
92,allotment option,7.605448423630241
93,plasma collection center,7.5963414634146345
94,collection supply,7.5963414634146345
95,debt financing,7.588922764227642
96,product candidate,7.550420168067227
97,predecessor product candidate,7.550420168067227
98,contract drug substance,7.544326241134751
99,regulatory approval,7.543766149870801
100,fixed obligation,7.542759094028826
101,term investment,7.539130434782608
102,biotechnology industry,7.537671232876712
103,blood plasma,7.535230352303524
104,contracting party,7.51981409001957
105,capital resources,7.518361581920903
106,method,7.514423076923077
107,requested access,7.494047619047619
108,development delays,7.49160447761194
109,growth company,7.481989708404803
110,intellectual property,7.469696969696971
111,source plasma,7.468483024213182
112,performance examples,7.454267125908917
113,response letter,7.444444444444445
114,tax liability,7.435771065182831
115,plasma plasma storage,7.435540069686411
116,debt facility,7.434483881192869
117,manufacturing scale,7.426623022367703
118,public offering,7.417812579577285
119,plasma,7.4166763916443
120,drug product,7.4147058823529415
121,final approval,7.411821705426357
122,contract testing laboratory,7.405920444033302
123,service period,7.405031446540881
124,traded option,7.401744719926538
125,accelerated filer,7.4
126,final product,7.398039215686274
127,cash flows,7.393685567010309
128,average number,7.392857142857143
129,external funding,7.38257691136156
130,equity offering,7.380131915466416
131,annual period,7.370827033068174
132,wa declared effective,7.364808362369338
133,transition period,7.363364779874214
134,equity offering,7.362064358514334
135,dividend yield,7.361111111111111
136,debt lender,7.350496838301716
137,regulatory approval,7.347383720930233
138,additional equity,7.346894409937888
139,substantial amount,7.342583732057416
140,byadma biocenters,7.342105263157895
141,bank credit facility,7.340753424657534
142,reporting period,7.335058437094188
143,loan,7.330498259910025
144,oxford finance,7.328358208955224
145,common stock,7.326273069036226
146,line basis,7.325757575757575
147,boca facility,7.324086757990868
148,deposit,7.315323041738136
149,trough level,7.303418803418803
150,insurance premium prepayment,7.293759512937595
151,development service,7.291009239516702
152,rent maintenance,7.285714285714286
153,compromised patient,7.272828014184397
154,tax asset,7.272372372372373
155,principal balance,7.271437522377372
156,operating activity,7.2695329294508495
157,potential commercialization,7.265116279069767
158,clinical trial,7.264317425083241
159,future policy,7.264096185737976
160,final payment,7.24748427672956
161,biologics license application,7.245371750289783
162,validation service,7.244244604316547
163,boca facility,7.244086757990868
164,auditing fee commercialization,7.240863787375416
165,service agreement,7.236430678466077
166,risk factors,7.233802816901408
167,cash runway,7.230876925035001
168,auditor provide,7.230769230769231
169,indebtedness,7.227010388611004
170,derived product,7.226836819451786
171,measurement period adjustments,7.221698113207547
172,stock option,7.212740011184987
173,stock option,7.212740011184987
174,business startups,7.206349206349206
175,adma biologics,7.202136752136752
176,equity investment loan,7.195740008783488
177,product,7.1952614379084965
178,market launch,7.193506493506494
179,term liquidity,7.189130434782609
180,significant risk,7.182189913675602
181,financial statement,7.180322054337802
182,wa approximately owned,7.17608695652174
183,facility fee,7.17583745827098
184,plasma,7.170785907859079
185,rsv titer,7.170731707317073
186,spot market,7.16969696969697
187,potential forfeiture,7.16956560864926
188,equity financing,7.1647604369457065
189,financing activity,7.160442754919499
190,plasma supply agreement,7.149438808547378
191,compensation expense,7.146716716716717
192,sale plasma,7.141186824239377
193,revenue recognition,7.138418079096045
194,compensation expense,7.13479302832244
195,clinical study,7.130143755615454
196,wa primarily attributable,7.129488158899924
197,adma biologics,7.126379176379177
198,measured baseline,7.115384615384615
199,expense,7.114033613445378
200,term manufacturing,7.109343200740055
201,owned subsidiary,7.107142857142858
202,reporting period,7.106165378932836
203,equity commitment,7.102846790890269
204,initial term,7.10103519668737
205,trial,7.095798319327731
206,expense,7.0945807259073845
207,term loan,7.085595081247256
208,pharmaceuticals corporation,7.0847107438016526
209,dr grossman,7.083333333333334
210,common stock,7.0742889420521
211,fda approval,7.071756947416813
212,additional financing,7.069332298136645
213,debt financing,7.06718363379286
214,product revenue,7.062647770972796
215,common stock,7.062536805299962
216,clinical manufacturing,7.061424732641111
217,fasb issued asu,7.058742727860375
218,antibody level,7.0576923076923075
219,virus,7.052631578947368
220,year,7.037962037962037
221,experience disruption,7.037671232876712
222,adma biocenters,7.0322176621744035
223,year adma biologics,7.028865578865578
224,plasma center expense,7.026341463414634
225,expense net,7.023506493506494
226,deferred revenue,7.014544205222172
227,cash flow,7.007909704941344
228,period,7.00761560965136
229,alternative process,7.004761904761905
230,ri approval,7.003488372093023
231,significant revenue,7.003471842536905
232,additional capital,6.999313962873284
233,stock option,6.997792921237897
234,outstanding debt,6.997542693680905
235,common stock,6.99470936247252
236,business requirement,6.992063492063492
237,development program,6.983452303698897
238,specialty immunoglobulin company,6.981989708404803
239,plasma inventory,6.954517564043565
240,transaction price allocate,6.939024390243903
241,commercial program,6.935514734022197
242,common stock,6.932874800637958
243,private placement,6.921052631578947
244,variance,6.921004566210046
245,antibody titer,6.920731707317073
246,initial term,6.915320910973085
247,public company,6.9138078902229845
248,fee accounting,6.909226190476191
249,facility,6.887456721360831
250,financial payment,6.87814955739484
251,credit market instability,6.878030303030302
252,company scommon stock,6.874334206012458
253,future commercialization,6.868101353696633
254,warning letter,6.856363813419028
255,taxes,6.849673202614379
256,validation testing,6.844927536231884
257,product candidate,6.838091400943939
258,pidd patients,6.833333333333334
259,discovery research program,6.833333333333333
260,month,6.830485527544351
261,test plasma donor,6.824912891986063
262,iii study,6.816666666666666
263,december wa derived,6.814460570029725
264,debt financing grant,6.813922764227643
265,ri wa filed,6.809523809523809
266,period balance,6.809377629458493
267,equity incentive plan,6.806418219461698
268,service,6.802380952380952
269,year,6.800666641783684
270,interim reporting pursuant,6.799554632722458
271,rsv antibody,6.795731707317073
272,increased cost,6.792648859635696
273,total principal,6.781011351909185
274,operating loss,6.778151260504202
275,fda approval,6.772240039204252
276,adequate quantity,6.769169960474309
277,stock option,6.766311439756416
278,business adma biologics,6.757692307692308
279,fda approves,6.740490797546013
280,product revenue,6.73645729478232
281,regulatory activity,6.726876321353066
282,arrangement development,6.725688328543617
283,initial term,6.723013218665392
284,related asset,6.722022382094324
285,location,6.720833333333334
286,source,6.7181471778995
287,deferred revenue,6.71525311084911
288,acquisition agreement,6.706943498978896
289,increased quantity,6.7032022351171285
290,february ri wa,6.692857142857143
291,net loss,6.691825821237586
292,party manufacturer development,6.683974607482071
293,bpc,6.679951690821256
294,regulatory approval,6.675079281183932
295,prepayment fee,6.673124592302674
296,future result,6.672215843857635
297,development service,6.670130118637581
298,cash flow asu,6.669674410823697
299,operation,6.6634304207119746
300,diligence fee,6.649450549450549
301,consulting service,6.644871794871794
302,fee,6.644814090019569
303,term loan,6.641150636802811
304,subordinated note,6.632634032634033
305,party contract manufacturer,6.632529704338216
306,licensing arrangement,6.630143701933388
307,note thereto,6.630069930069929
308,limitation,6.629625255865218
309,prepaysa loan,6.628454354869449
310,equity financing volatility,6.628442028985507
311,cash,6.6259657867905295
312,granted biotest ag,6.616192225283134
313,financial statement,6.61301436203011
314,amount,6.607518796992482
315,approximately million wa,6.595867176301959
316,gender pidd patient,6.59375
317,pidd patient,6.59375
318,existing account,6.592262576133544
319,actual forfeiture,6.589891067538126
320,sell wa allocated,6.585714285714286
321,recurring adjustment,6.582375478927203
322,customer bpc,6.572753623188405
323,term loan,6.561785557437732
324,term fee payment,6.560424235321692
325,important factor,6.5600000000000005
326,deferred revenue,6.558770249448216
327,year period,6.558320395035309
328,additional staff,6.556349206349206
329,term loan,6.5522617479139225
330,company,6.54865637507147
331,ri biotest ag,6.534710743801653
332,senior debt,6.5318833530215645
333,operating expense,6.531809954751131
334,early adoption,6.525058275058274
335,earlier application,6.514204545454545
336,ri patent,6.504166666666667
337,product candidate,6.502801120448179
338,adverse effect,6.499504478749762
339,subtopic disclosure,6.494092373791622
340,outstanding issue,6.4904761904761905
341,deferred revenue,6.490170137903319
342,input assumption,6.4824016563147
343,production cost,6.469244604316547
344,period,6.46455525606469
345,exercise price,6.459884467265725
346,plasma collection increase,6.446341463414634
347,risk group,6.442136150234742
348,loan agreement,6.4403027323381306
349,iv occurrence,6.437710437710438
350,million commitment,6.430494505494505
351,million wa recorded,6.428871128871129
352,net proceeds,6.426978681695662
353,financial payment,6.419513853476118
354,debt liability,6.411843839132425
355,licensed gha,6.407157464212679
356,registration statement,6.405057876634601
357,loan amount,6.403983443457128
358,reason adma,6.391025641025641
359,prepaid expense,6.39031746031746
360,additional fund,6.386507936507936
361,million consisting primarily,6.375994284353418
362,lsa bear interest,6.375007506155048
363,bivigam,6.374522442282902
364,additional equity,6.3707039337474125
365,term loan,6.364166509818684
366,specialty treatment organization,6.357142857142858
367,loan amount,6.347634237107921
368,vesting period,6.345665055356307
369,timing progress,6.343869731800766
370,date,6.336923688394277
371,term loan,6.326335821987996
372,drug product,6.321372549019608
373,total revenue,6.317116831324209
374,license agreement,6.312915719941094
375,continuing implementation,6.307157464212678
376,party vendor,6.297591867797347
377,sale,6.294845360824742
378,cash flow,6.257909704941344
379,financial statement,6.2557937524510105
380,account payable million,6.2479735318445
381,period earnings,6.246389471232239
382,expense capital requirement,6.245980629539952
383,net loss,6.24567197508374
384,debt issue cost,6.2371370499419285
385,vendor payment,6.236173325490551
386,administrative expenses,6.230921052631579
387,provisional amount,6.228947368421053
388,accounting standard,6.221682551319649
389,equity interest,6.21988354201793
390,prior lender,6.21957671957672
391,evaluate ri ri,6.213793103448276
392,june adma,6.2060116354234
393,million net,6.203659384094166
394,planning activity,6.203254110230855
395,cumulative loss,6.202714932126697
396,product revenue cost,6.194790628115653
397,funding date,6.193317326930773
398,net cash,6.188413865028081
399,milestone payment,6.187227866473149
400,interim period,6.18178519593614
401,party manufacturing vendor,6.1801334008780815
402,fold increase,6.175
403,debt security,6.167727112053729
404,shipment product revenue,6.165944474269499
405,early adoption,6.159660107334526
406,plasma development operation,6.155543028405215
407,earlier application,6.148806377730796
408,fda approval,6.14303577341262
409,securities exchange act,6.134453781512605
410,asset,6.133312704674969
411,theoriginal lsa,6.124824355971897
412,product development quality,6.110477026631549
413,aggregate amount,6.097518796992481
414,term loan tranche,6.085595081247256
415,approval requirement summary,6.0844407530454045
416,employee stock option,6.078811439756416
417,forfeiture rate,6.075661375661375
418,asset debt disclosure,6.074608705270726
419,impairment test,6.070833333333333
420,development segment,6.0676675274653125
421,proposed acquisition,6.067004048582996
422,adma biocenters,6.066464237516869
423,customer product revenue,6.06645729478232
424,license revenue,6.066113061709061
425,adoption,6.062729507934987
426,june adma,6.0576923076923075
427,march adma,6.050366905621367
428,principal amount,6.047017543859649
429,modification,6.034134615384616
430,actual result,6.03393665158371
431,security agreement lsa,6.026368906073585
432,increased sale,6.018249616143891
433,expansion activity management,6.010109159943047
434,employee debt loan,5.985387410692288
435,adverse event,5.9846394984326015
436,deferred revenue,5.98301267369064
437,subject receiving ivig,5.972046041813483
438,biotest ag biotest,5.969421487603306
439,cost,5.957543027748507
440,account,5.951270235141203
441,market condition,5.930548730548731
442,note payable due,5.924941724941725
443,acceleration,5.90934065934066
444,potential timing,5.904644767072877
445,sale revenue,5.900579457236805
446,research,5.880858863576852
447,company,5.873418279833374
448,securities act section,5.869747899159663
449,significant volatility,5.869599217986314
450,period presentation,5.861774086616855
451,future event,5.851260936695831
452,adma,5.8428620928620925
453,term loan,5.835595081247256
454,development business cost,5.8318822553897185
455,states sale,5.828178694158075
456,loan balance,5.821761630930075
457,additional indebtedness,5.8191511387163555
458,impairment loss,5.812009803921568
459,manufacturing process,5.786085781830462
460,prospectively beginning january,5.776623376623376
461,asset liability revenue,5.774038994128725
462,hercules loan,5.768157768157769
463,bla approval,5.752189670794322
464,commercialization activity delay,5.745908699397072
465,volatility,5.74029304029304
466,representation warranty,5.6923076923076925
467,commencement date,5.692296918767507
468,planned improvement,5.633333333333333
469,interest rate,5.614991512552488
470,lsa doe,5.609744990892532
471,debt liability,5.579301362475452
472,term assumption,5.568357487922706
473,sale,5.547875663855045
474,equity issuance cost,5.5037625418060205
475,cost,5.4835714285714285
476,valuation allowance,5.436363636363636
477,human plasma,5.427591463414634
478,amount,5.385296574770258
479,management belief,5.381746824603968
480,company director,5.358180184595279
481,management,5.33770282306471
482,actual result,5.3031674208144794
483,virus infection bivigam,5.267672707031975
484,bivigam,5.259692028985507
485,approval,5.231266149870801
486,patent protection,5.1875
487,drug,5.15952380952381
488,immune system,5.15130023640662
489,fasb issued,5.146978021978022
490,accounting guidance,5.144088491295938
491,company,5.121027141559884
492,clinical trial,5.114317425083241
493,plasma center,5.0963414634146345
494,clinical program,5.084905660377359
495,potential approval,5.034883720930233
496,letter,5.015873015873016
497,bacterial infections,5.0
498,nabi,5.0
499,final payment,4.99748427672956
500,event,4.996708910502014
501,additional personnel,4.992857142857143
502,bla resubmission,4.991980241980242
503,fiscal year,4.988344988344988
504,adma biologics,4.97991452991453
505,previous debt,4.968730456535335
506,ri submitted,4.955555555555556
507,entity,4.946638289143033
508,wa related,4.93710174717369
509,boca facility,4.924086757990867
510,private placement,4.921052631578947
511,alternative future,4.902985074626866
512,initial application,4.9004329004329
513,month pursuant,4.897801544860369
514,dilutive security,4.867494824016563
515,resource,4.863636363636363
516,anti dilutive,4.851190476190476
517,cash,4.849042709867453
518,potential product,4.846101231190151
519,fee payable,4.844322344322345
520,equity security,4.840579710144928
521,development plasma,4.825445941026574
522,facility fee,4.822896281800391
523,normal source,4.822141560798547
524,rsv plasma,4.817073170731708
525,deferred taxes,4.816816816816817
526,hyperimmune globulin,4.8125
527,revenue,4.797941888619855
528,amortization date,4.797058823529412
529,stockholders equity,4.782608695652174
530,compensation expense,4.781851851851852
531,additional staff,4.7785714285714285
532,insurance charges,4.777777777777778
533,making ri,4.775
534,regulatory approval,4.765988372093023
535,equity financing,4.761775362318841
536,cash flow,4.757909704941344
537,patent,4.7575
538,commercial program,4.756410256410256
539,wa predicated,4.742857142857143
540,wa paid,4.742857142857143
541,wa conditioned,4.742857142857143
542,plasma quantity,4.737250554323725
543,additional equity,4.727846790890269
544,financial reporting,4.727358937885254
545,period,4.721698113207547
546,capital,4.7207425343018565
547,future financing,4.715485074626866
548,firm commitment,4.708333333333334
549,ri implementation,4.699999999999999
550,product application,4.688948306595366
551,outstanding warrant,4.68543956043956
552,annual period,4.685112747353889
553,development program,4.67910447761194
554,donor collection,4.678571428571429
555,rsv titer,4.670731707317073
556,manufacturing capability,4.670212765957446
557,financing fee,4.669642857142858
558,debt security,4.667727112053729
559,accurate overview,4.666666666666666
560,commercial production,4.656410256410256
561,limitation,4.654761904761905
562,expense,4.653404255319149
563,wa recorded,4.651948051948052
564,deferred revenue,4.649679340357307
565,procure plasma,4.646341463414634
566,period,4.642750744786495
567,ri prior,4.640740740740741
568,line item,4.638888888888889
569,manufacturing facility,4.635966190614981
570,primarily related,4.635421074904782
571,reporting requirement,4.635338345864662
572,common stock,4.629844497607655
573,higher cost,4.625
574,ri adma,4.624358974358975
575,traded option,4.62396694214876
576,manufacturing supply,4.620212765957447
577,balance sheet,4.613605442176871
578,loan facility,4.6122180711221805
579,option,4.605448423630241
580,option,4.605448423630241
581,including regulatory,4.600171232876712
582,attributableto,4.6
583,increased cost,4.598404255319149
584,drug development,4.595771144278607
585,immune suppressed,4.595744680851064
586,additional financing,4.5910714285714285
587,fda focused,4.590490797546012
588,debt financing,4.588922764227642
589,potential indication,4.5813953488372094
590,titer,4.576923076923077
591,principal balance,4.575008950948801
592,rsv ri,4.570731707317073
593,financial payment,4.570457249702533
594,adma biocenters,4.566464237516869
595,curtail activity,4.565891472868217
596,net cash,4.5568349176596605
597,applicableloan prepaid,4.555555555555555
598,ivig regularly,4.555555555555555
599,cash balance,4.553124342520514
600,legal accounting,4.552083333333334
601,product candidate,4.550420168067227
602,development expenses,4.547525530243519
603,collaborative arrangement,4.546583850931677
604,regulatory activity,4.545058139534884
605,transition relief,4.541666666666666
606,product manufacturer,4.537433155080214
607,clinical safety,4.537286612758311
608,blood plasma,4.535230352303524
609,adma,4.532051282051282
610,month interest,4.530668677727501
611,foreseeable future,4.527985074626866
612,significant amount,4.527334465195246
613,operating activity,4.526675786593707
614,marietta ga,4.520833333333334
615,stock option,4.516311439756416
616,development costs,4.512437810945274
617,consulting fee,4.510989010989011
618,physician patient,4.510416666666667
619,fda licensed,4.507157464212678
620,party manufacturer,4.50487012987013
621,month basis,4.503862150920975
622,supply agreement,4.503097345132744
623,additional period,4.500269541778976
624,bank sboard,4.5
625,legal proceeding,4.5
626,successfully develop,4.5
627,immunoglobulin rationale,4.5
628,existing commitment,4.496212121212121
629,prepaid expense,4.485555555555555
630,existing resource,4.484848484848484
631,toxicology testing,4.478260869565217
632,reduced testing,4.478260869565217
633,access capital,4.476694915254237
634,reporting unit,4.473684210526316
635,account payable,4.471050454921423
636,intellectual property,4.46969696969697
637,facility,4.465753424657534
638,limitation statement,4.457349081364829
639,revenue,4.455084745762711
640,approval,4.453488372093023
641,approval,4.453488372093023
642,additional indebtedness,4.452484472049689
643,material forfeiture,4.449336128581411
644,voting class,4.444444444444445
645,security agreement,4.444401692958831
646,effective january,4.443065589013662
647,fasb belief,4.441558441558442
648,primarily consisted,4.4411764705882355
649,expense,4.439803921568627
650,transaction price,4.439024390243903
651,commercial development,4.435514734022197
652,administrative expenses,4.430921052631579
653,jobs,4.428571428571429
654,commercial manufacturing,4.426623022367703
655,related party,4.426387461459404
656,price,4.42479674796748
657,license fee,4.42271662763466
658,warrant,4.4217032967032965
659,modification accounting,4.41875
660,drug administration,4.416666666666666
661,initial term,4.415320910973085
662,development activity,4.411662617146824
663,total revenue,4.4080259222333
664,early adoption,4.403846153846153
665,high level,4.4006410256410255
666,ri ranged,4.4
667,standardize ri,4.4
668,production,4.4
669,existing debt,4.397634885439763
670,itscommon stock,4.392344497607656
671,standardized level,4.392307692307693
672,prior loan,4.3872053872053876
673,primarily attributable,4.386631016042781
674,underwritten sale,4.383734249713632
675,adverse condition,4.378787878787879
676,lender,4.377104377104377
677,securities,4.369747899159663
678,drug safety,4.369047619047619
679,funded loan,4.3686868686868685
680,increased inventory,4.364913689281413
681,substantial doubt,4.363636363636363
682,specific date,4.362443438914028
683,financial performance,4.357588357588357
684,primary endpoint,4.357142857142858
685,option activity,4.356525081683644
686,ri data,4.356521739130435
687,net realizable,4.35064935064935
688,development process,4.350533049040512
689,process development,4.350533049040512
690,balance,4.346938775510204
691,incur loss,4.341176470588236
692,approves,4.340490797546012
693,collaborative agreement,4.3388116308470295
694,proprietary technology,4.333333333333334
695,dr jerrold,4.333333333333334
696,norcross ga,4.333333333333334
697,asc specifically,4.333333333333334
698,united states,4.333333333333333
699,staff,4.333333333333333
700,total amount,4.33188854489164
701,antibody,4.326923076923077
702,bpc,4.326086956521739
703,product revenue,4.319790628115653
704,previous submission,4.3173076923076925
705,normal donor,4.316502463054187
706,primarily held,4.3161764705882355
707,prior lender,4.314814814814815
708,cumulative effect,4.311111111111111
709,exemption,4.3076923076923075
710,ri offset,4.304761904761905
711,current debt,4.301114122252334
712,implementation approach,4.3
713,contract manufacturing,4.297872340425531
714,interim period,4.297169811320755
715,term fee,4.296273291925466
716,approval,4.2939791696390355
717,due diligence,4.292307692307692
718,common virus,4.290131578947369
719,terminology,4.287671232876712
720,factor,4.287671232876712
721,client,4.287671232876712
722,exploring including,4.287671232876712
723,gross proceeds,4.286096256684491
724,requested documentation,4.285714285714286
725,additional detail,4.2785714285714285
726,additional paid,4.2785714285714285
727,subsequently borrowed,4.276923076923078
728,fda issued,4.27318310523832
729,year period,4.2706491621585965
730,existing loan,4.267676767676768
731,entire study,4.266666666666667
732,pediatric study,4.266666666666667
733,finished product,4.264705882352941
734,commercial infrastructure,4.256410256410256
735,commercial viability,4.256410256410256
736,annum equal,4.25
737,negative pledge,4.25
738,finish provider,4.25
739,polyclonal antibody,4.25
740,antibody profile,4.25
741,received ri,4.249056603773585
742,administrative service,4.245833333333334
743,forfeiture rate,4.242328042328042
744,debt discount,4.237961225766104
745,expense,4.237692307692307
746,market,4.236363636363636
747,disclosure requirement,4.23469387755102
748,risk factors,4.233802816901409
749,note payable,4.232634032634032
750,current cash,4.230876925035001
751,full year,4.23076923076923
752,financial position,4.229383229383229
753,amount,4.228947368421053
754,provisional amount,4.228947368421053
755,date,4.2253196930946295
756,company,4.224846851261946
757,adma,4.2243589743589745
758,operating expense,4.224117647058823
759,georgia facility,4.222510181414291
760,word,4.222222222222222
761,table,4.222222222222222
762,subsequent period,4.221698113207547
763,measurement period,4.221698113207547
764,net exercise,4.21907040328093
765,debt liability,4.217599234815878
766,potential risk,4.215198165738618
767,related disclosure,4.214652767581853
768,credit market,4.211363636363636
769,exercise price,4.209884467265725
770,high degree,4.208333333333334
771,high dose,4.208333333333334
772,characteristic significantly,4.208333333333333
773,judgment,4.208333333333333
774,principal amount,4.207017543859649
775,infectious disease,4.204761904761905
776,plasma,4.20189701897019
777,healthcare,4.2
778,whichwe,4.2
779,related information,4.194244604316546
780,exchange act,4.193277310924369
781,reimbursement level,4.1923076923076925
782,date,4.188235294117647
783,primary stockholder,4.182142857142857
784,immune deficiency,4.1819515774027884
785,financial statement,4.180322054337802
786,plasma,4.1796747967479675
787,donor,4.178571428571429
788,donor,4.178571428571429
789,asset,4.177777777777777
790,account,4.174347158218126
791,substantive process,4.171428571428571
792,rsv survived,4.170731707317073
793,amended based,4.17042042042042
794,chemistry manufacturing,4.170212765957446
795,company,4.167703994119089
796,additional consideration,4.167460317460318
797,medical reason,4.166666666666667
798,commercially viable,4.166666666666666
799,projected revenue,4.1661958568738235
800,annual report,4.160384331116038
801,liability,4.1599264705882355
802,fee,4.152014652014652
803,loan tranche,4.146464646464647
804,goodwill,4.1375
805,cash expense,4.136185567010309
806,distribution plan,4.134920634920634
807,biotest ag,4.134710743801653
808,middle east,4.133333333333334
809,renal impairment,4.133333333333333
810,expansion activity,4.132558139534884
811,contract filler,4.127659574468085
812,fda requested,4.126205083260298
813,approximately year,4.125038005472788
814,expense,4.124244604316547
815,unvested option,4.12396694214876
816,license agreement,4.118671115624547
817,significant impact,4.117617866004963
818,commercialization activity,4.116279069767442
819,commercialize ri,4.114285714285714
820,business combination,4.111111111111111
821,development expense,4.1091044776119405
822,senior management,4.108320251177394
823,recorded related,4.1033355134074565
824,capital contribution,4.101694915254237
825,cash consideration,4.095074455899198
826,financial condition,4.094185094185094
827,ri due,4.092307692307692
828,net loss,4.091825821237586
829,applicable notice,4.091666666666667
830,ongoing basis,4.090909090909091
831,term loan,4.085595081247256
832,biotest aktiengesellschaft,4.0847107438016526
833,liability,4.084033613445378
834,consulting expense,4.083846153846154
835,dr grossman,4.083333333333334
836,fda prior,4.081231538286753
837,applicable draw,4.066666666666666
838,impairment charge,4.066666666666666
839,conducted prior,4.064270152505447
840,lender warrant,4.0630850630850635
841,common stockholder,4.0625
842,key assumption,4.062233589087809
843,libor rate,4.057142857142857
844,assumption,4.0557871749056975
845,additional million,4.055494505494505
846,revenue,4.055084745762712
847,respective agreement,4.053097345132743
848,principal stockholder,4.053070175438596
849,full exercise,4.05023923444976
850,year,4.048951048951048
851,calendar year,4.048951048951048
852,licensing arrangement,4.048748353096179
853,rsv,4.045731707317073
854,increase wa,4.042857142857143
855,adverse event,4.039184952978056
856,operating loss,4.035294117647059
857,actual result,4.03393665158371
858,corporate collaboration,4.028225806451613
859,table,4.022222222222222
860,disclosure threshold,4.020408163265306
861,payment,4.014150943396226
862,clinical evaluation,4.013477088948787
863,business activity,4.010335917312661
864,potential evaluation,4.009966777408638
865,party vendor,4.009920634920634
866,million adma,4.001282051282051
867,korean ministry,4.0
868,collateral agent,4.0
869,inthecompany sresearch,4.0
870,direct deduction,4.0
871,north africa,4.0
872,seized remedies,4.0
873,collateral,4.0
874,underwriter,4.0
875,restriction,4.0
876,regularly reviewed,4.0
877,previously paid,4.0
878,tranche,4.0
879,successfully resubmit,4.0
880,proper specification,4.0
881,payer concurrence,4.0
882,streptococcus,4.0
883,genetic disorder,4.0
884,genetic defect,4.0
885,american academy,4.0
886,mild cold,4.0
887,healthy adult,4.0
888,national distributor,4.0
889,effectively identify,4.0
890,selected territory,4.0
891,remain consistent,4.0
892,site advertising,4.0
893,profitability,4.0
894,region,4.0
895,greatly reduced,4.0
896,local government,4.0
897,consumer spending,4.0
898,irrevocably opt,4.0
899,readily apparent,4.0
900,inherently uncertain,4.0
901,trading history,4.0
902,solution,4.0
903,documentation,4.0
904,eighty percent,4.0
905,ten percent,4.0
906,area,4.0
907,convergence,4.0
908,vice chairman,4.0
909,pascack bankcorp,4.0
910,lakeland bancorp,4.0
911,biocenter,4.0
912,worked diligently,4.0
913,canada australia,4.0
914,eventually refiling,4.0
915,timely manner,4.0
916,inflation inflation,4.0
917,acute exposure,4.0
918,infant,4.0
919,household exposure,4.0
920,highest priority,4.0
921,technical corrections,4.0
922,practical expedient,4.0
923,annual assessment,3.9928263988522237
924,bpc,3.9927536231884053
925,infection,3.987987987987988
926,significant dilution,3.9858870967741935
927,investment results,3.9846153846153847
928,recognize revenue,3.9836561743341408
929,final review,3.9833333333333334
930,marketing activity,3.9825581395348837
931,amount,3.9789473684210526
932,amount,3.9789473684210526
933,party customer,3.978809523809524
934,office space,3.9772727272727275
935,recognized totaled,3.9770867430441896
936,transaction,3.972560975609756
937,date,3.972058823529412
938,performance obligation,3.9706368899917286
939,debt,3.9687304565353347
940,underwriting discount,3.9615384615384617
941,includes general,3.961290322580645
942,beginning january,3.9584415584415584
943,minimal data,3.9565217391304346
944,safety profile,3.9523809523809526
945,ordinarily lead,3.9523809523809526
946,georgia,3.944256756756757
947,remaining million,3.9435897435897433
948,term,3.9391304347826086
949,term,3.9391304347826086
950,contractual term,3.9391304347826086
951,favorable term,3.9391304347826086
952,remediation effort,3.9384615384615387
953,interest,3.935897435897436
954,delay,3.933977455716586
955,noncash charge,3.9333333333333336
956,biotest transaction,3.932271719411409
957,completed prior,3.931917211328976
958,warrant liability,3.9301874595992246
959,accrued expense,3.9299999999999997
960,promotion expense,3.9299999999999997
961,biotest assets,3.925619834710744
962,million loan,3.9233877233877235
963,obligation,3.9193548387096775
964,proposed acquisition,3.917004048582996
965,pidd meeting,3.916666666666667
966,pidd population,3.916666666666667
967,ii affirmatively,3.9166666666666665
968,company,3.9146820160971103
969,public company,3.9138078902229845
970,lessee,3.9117647058823533
971,accounting principle,3.9110576923076925
972,timely basis,3.909090909090909
973,initially recorded,3.909090909090909
974,entity,3.9075391180654337
975,additional submission,3.9035714285714285
976,corporate column,3.903225806451613
977,corporate priority,3.903225806451613
978,private company,3.90304233998375
979,shipment revenue,3.901238591916558
980,loan matures,3.8964646464646466
981,adma,3.8910256410256414
982,amount,3.8880382775119617
983,information,3.8846153846153846
984,publicly update,3.883040935672515
985,contract fill,3.877659574468085
986,management,3.8775510204081636
987,management,3.8775510204081636
988,treated approximately,3.876086956521739
989,expense,3.8754545454545455
990,transportation cost,3.875
991,warrant,3.8736263736263736
992,topic revenue,3.8732665639445303
993,risk,3.8713028169014083
994,potential refinancing,3.867109634551495
995,interest expense,3.865897435897436
996,implementation guidance,3.8636363636363633
997,commercial initiative,3.8564102564102565
998,purchase price,3.8561692969870873
999,approximately million,3.853010033444816
1000,future event,3.851260936695831
1001,current stockholder,3.8496913580246916
1002,prepayment premiumand,3.8493150684931505
1003,prepayment penalty,3.8493150684931505
1004,voluntary prepayment,3.8493150684931505
1005,received palivizumab,3.849056603773585
1006,full force,3.8484848484848486
1007,acceptable term,3.8482213438735178
1008,rsv patient,3.8478150406504064
1009,entity,3.8436293436293436
1010,loan maturity,3.8434343434343434
1011,anticipated due,3.842307692307692
1012,licensing agreement,3.840976133011531
1013,lease ha,3.8366666666666664
1014,market acceptance,3.8363636363636364
1015,biotest evidenced,3.834710743801653
1016,material impact,3.833381712626996
1017,money judgment,3.833333333333333
1018,fully transferable,3.833333333333333
1019,efficacy endpoint,3.833333333333333
1020,complex judgment,3.833333333333333
1021,business unit,3.8304093567251463
1022,operational expense,3.83
1023,previously conducted,3.8235294117647056
1024,development inventory,3.8206139115742044
1025,completed contract,3.8188360450563206
1026,topic,3.8181818181818183
1027,evaluate ri,3.8137931034482757
1028,loan document,3.813131313131313
1029,regulatory strategy,3.8125
1030,substantial completion,3.808080808080808
1031,treatment center,3.8071428571428574
1032,financial statements,3.8063063063063063
1033,aggregate number,3.8042857142857143
1034,adjustment,3.8023391812865497
1035,company,3.8019897084048027
1036,customer revenue,3.8017514124293785
1037,pidd commercialization,3.800387596899225
1038,expected term,3.8002415458937198
1039,present fairly,3.8
1040,necessarily indicative,3.8
1041,protein,3.8
1042,present separately,3.8
1043,issue,3.7940476190476193
1044,working capital,3.7940026075619295
1045,efficacy data,3.789855072463768
1046,therapeutic research,3.787878787878788
1047,condition,3.787878787878788
1048,adjustment,3.787301587301587
1049,prepayment charge,3.782648401826484
1050,subsidiaries,3.782051282051282
1051,contingent asset,3.7777777777777777
1052,operational management,3.777551020408163
1053,convertible debt,3.7764227642276422
1054,company,3.7677039941190884
1055,supplier,3.764864864864865
1056,exchange commission,3.764705882352941
1057,fda resubmission,3.7635677206229357
1058,estimated expense,3.763333333333333
1059,interest,3.760897435897436
1060,thing,3.758893280632411
1061,statement,3.7586311326468804
1062,covenant,3.7586206896551726
1063,guidance,3.757880967952911
1064,georgia,3.756756756756757
1065,funding million,3.756514913657771
1066,december,3.755813953488372
1067,dated december,3.755813953488372
1068,acquisition transaction,3.75140712945591
1069,selected country,3.75
1070,immediately precedes,3.75
1071,historical experience,3.75
1072,consideration,3.75
1073,date,3.7470588235294118
1074,itsmaturity date,3.7470588235294118
1075,customer,3.7466666666666666
1076,special note,3.745454545454545
1077,approximately billion,3.742753623188406
1078,collect approximately,3.742753623188406
1079,period,3.740216631726066
1080,adjusted including,3.732115677321157
1081,agreement,3.731668773704172
1082,interest,3.730769230769231
1083,customer account,3.730537634408602
1084,deficiency,3.729064039408867
1085,reportable segment,3.7272727272727275
1086,segment,3.7272727272727275
1087,funding date,3.726650660264106
1088,patient year,3.726034382284382
1089,expense,3.724871794871795
1090,current report,3.7216610549943887
1091,fund adma,3.7132478632478634
1092,differ materially,3.7114285714285717
1093,asset,3.7063492063492065
1094,sufficient cash,3.7061855670103094
1095,company doe,3.704211930627025
1096,term covenant,3.697751124437781
1097,quarterly report,3.6969696969696972
1098,attestation report,3.6969696969696972
1099,substantially attributable,3.6954545454545453
1100,operating expenditure,3.6941176470588233
1101,school,3.6923076923076925
1102,hospitalization,3.6923076923076925
1103,core principle,3.6923076923076925
1104,successfully completed,3.6911764705882355
1105,completed revenues,3.6911764705882355
1106,adequate fund,3.688888888888889
1107,selling general,3.688888888888889
1108,employee option,3.68646694214876
1109,begin repaying,3.685714285714286
1110,occurs depending,3.6833333333333336
1111,expense,3.6799999999999997
1112,assumption,3.6772068511198945
1113,patient living,3.677083333333333
1114,patient,3.677083333333333
1115,timing related,3.677003225006202
1116,market market,3.672727272727273
1117,wide range,3.666666666666667
1118,step,3.666666666666667
1119,successfully close,3.666666666666667
1120,step approach,3.666666666666667
1121,asset,3.6527777777777777
1122,assumption management,3.645666962437149
1123,filing fee,3.6428571428571432
1124,manufacture,3.6399999999999997
1125,lease existing,3.6378787878787877
1126,risk,3.6338028169014085
1127,numerous risk,3.6338028169014085
1128,risk factor,3.6338028169014085
1129,uncertainty,3.6333333333333333
1130,reason,3.6333333333333333
1131,materially affect,3.6314285714285717
1132,oxford pursuant,3.631388511985527
1133,limit,3.6296296296296298
1134,written notice,3.625
1135,company,3.6248468512619456
1136,market condition,3.624242424242424
1137,adjustment amount,3.623391812865497
1138,proposed treatment,3.6203007518796992
1139,additional share,3.6202380952380953
1140,iii license,3.615573770491803
1141,amount,3.6153110047846893
1142,expense,3.6085714285714285
1143,date,3.608169934640523
1144,change,3.608108108108108
1145,amount,3.607518796992481
1146,analyze performance,3.6068376068376065
1147,current lsa,3.6066585711394454
1148,prepayment,3.5993150684931505
1149,footnote disclosure,3.591836734693877
1150,fda request,3.5904907975460123
1151,current guidance,3.588327721661055
1152,lsa events,3.581967213114754
1153,adjustment,3.5730158730158728
1154,influenza type,3.571428571428571
1155,pneumonia type,3.571428571428571
1156,negatively impact,3.569230769230769
1157,purchase agreement,3.5678032274856846
1158,sg amp,3.5666666666666664
1159,operating result,3.5633484162895925
1160,customers,3.555555555555556
1161,promised good,3.5555555555555554
1162,million million,3.5538461538461537
1163,company,3.5534182798333744
1164,statement,3.5525871766029247
1165,fda identified,3.5488241308793453
1166,updated standard,3.5483870967741935
1167,standard introduces,3.5483870967741935
1168,claim,3.5454545454545454
1169,comparison,3.5416666666666665
1170,limited revenue,3.5256729810568297
1171,asu require,3.5204603580562663
1172,data,3.5120772946859904
1173,plan,3.5
1174,varying interpretation,3.5
1175,secondary outcome,3.5
1176,acquirer record,3.5
1177,timeliness clarity,3.5
1178,premises,3.5
1179,time period,3.498806546942487
1180,forego sale,3.4948453608247423
1181,sale,3.4948453608247423
1182,operations,3.4875
1183,entity satisfies,3.4864864864864864
1184,company,3.481989708404803
1185,company,3.481989708404803
1186,company,3.481989708404803
1187,company prepays,3.481989708404803
1188,company,3.481989708404803
1189,guidance,3.4754010695187167
1190,amendment,3.4721011333914555
1191,btbu,3.466666666666667
1192,loan amendment,3.4572754572754576
1193,lease term,3.455797101449275
1194,prepayment,3.449315068493151
1195,historical fact,3.4444444444444446
1196,maturity date,3.444028520499109
1197,effective prospectively,3.4401330376940136
1198,uncertainty,3.4333333333333336
1199,overhead comprised,3.428571428571429
1200,commercialization effort,3.4221824686940967
1201,inventory,3.4184325108853413
1202,entity,3.415057915057915
1203,method research,3.4102564102564106
1204,extension term,3.4097186700767264
1205,december adoption,3.409660107334526
1206,inventory assumption,3.40962537599125
1207,guidance,3.404127161182376
1208,forward period,3.403516295025729
1209,acquisition date,3.4009049773755655
1210,fda accepted,3.3960463531015677
1211,office building,3.393939393939394
1212,company,3.391080617495712
1213,contract determine,3.390817469204927
1214,exclusive manufacture,3.3899999999999997
1215,amended lsa,3.3875227686703098
1216,loss,3.377540106951872
1217,effective date,3.369010043041607
1218,approved globally,3.3666666666666667
1219,perform interim,3.361185983827493
1220,governmental regulation,3.357142857142857
1221,hepatitis,3.357142857142857
1222,rsv form,3.3549422336328627
1223,ongoing discussion,3.3484848484848486
1224,expected timing,3.3438697318007664
1225,current estimate,3.3435319377348365
1226,face amount,3.342583732057416
1227,risk,3.342136150234742
1228,infection,3.3415233415233416
1229,classified statement,3.3406824146981626
1230,comparable terminology,3.333333333333333
1231,fairness opinion,3.333333333333333
1232,company,3.3310463121783878
1233,operation,3.3300970873786406
1234,income statement,3.3256286512573023
1235,pk subject,3.325581395348837
1236,share amount,3.3206140350877194
1237,completion cost,3.3194444444444446
1238,current expectation,3.318809005083515
1239,oxford,3.317369197966213
1240,march forward,3.3166496424923393
1241,comparable amount,3.3122807017543856
1242,uncertainty,3.3119047619047617
1243,compliance issue,3.307936507936508
1244,complication,3.3076923076923075
1245,marked increase,3.3
1246,deficiency,3.2945402298850572
1247,marketing effort,3.2884615384615383
1248,company,3.287545263960358
1249,subsequently expensed,3.287449392712551
1250,fulfill order,3.2857142857142856
1251,order,3.2857142857142856
1252,entitled compositions,3.2857142857142856
1253,time point,3.2771084337349397
1254,time consuming,3.2771084337349397
1255,time frame,3.2771084337349397
1256,time horizon,3.2771084337349397
1257,company,3.2768615032765975
1258,adversely affect,3.274285714285714
1259,historical result,3.269230769230769
1260,march april,3.259831460674157
1261,circumstance,3.25
1262,amortization date,3.2470588235294118
1263,company,3.231989708404803
1264,default,3.230769230769231
1265,approximately half,3.229933110367893
1266,staffing,3.2142857142857144
1267,company,3.2092624356775303
1268,continued duration,3.207792207792208
1269,current portion,3.206509539842873
1270,million comprised,3.2054945054945057
1271,greater rise,3.2
1272,depreciation amortization,3.1923076923076925
1273,applied prospectively,3.186602870813397
1274,read carefully,3.1818181818181817
1275,fold increase,3.175
1276,company,3.1731661789930383
1277,result,3.1538461538461537
1278,entity,3.153153153153153
1279,transfer ownership,3.1515151515151514
1280,defined term,3.139130434782609
1281,business plan,3.134920634920635
1282,internal control,3.1333333333333333
1283,bla resubmission,3.130869130869131
1284,general operation,3.130097087378641
1285,company,3.1183533447684395
1286,change,3.118243243243243
1287,prospectively retrospectively,3.118181818181818
1288,concern uncertainty,3.107017543859649
1289,business day,3.1033591731266146
1290,loss,3.10287859824781
1291,increase general,3.1
1292,thefirst anniversary,3.096774193548387
1293,income effect,3.096057347670251
1294,customer,3.08
1295,connection,3.0769230769230766
1296,safety,3.0700280112044815
1297,marketing estimate,3.068840579710145
1298,secured obligation,3.0622119815668203
1299,discontinue,3.058201058201058
1300,estimated fair,3.0543859649122806
1301,asia,3.0508474576271185
1302,company,3.0248468512619455
1303,research,3.0245098039215685
1304,estimate due,3.011148272017837
1305,concern assessment,3.003095975232198
1306,company lease,2.9986563750714694
1307,company,2.981989708404803
1308,assumption,2.9681159420289855
1309,day duration,2.9619450317124736
1310,inventory,2.9596912521440824
1311,assumption form,2.9523264683447747
1312,purchase share,2.856372549019608
1313,fund operation,2.8189859762675296
1314,estimate,2.818840579710145
1315,company,2.725232951648046
1316,increased,2.723404255319149
1317,implied fair,2.7210526315789476
1318,fasb,2.7142857142857144
1319,america gaap,2.7105263157894735
1320,company,2.704211930627025
1321,outstanding,2.6964285714285716
1322,beginning,2.6857142857142855
1323,share computation,2.675
1324,plasma,2.6463414634146343
1325,extended,2.6
1326,investment,2.6
1327,month,2.5947712418300655
1328,potential,2.5813953488372094
1329,transition,2.5416666666666665
1330,trial,2.5294117647058822
1331,operation,2.5119152691968227
1332,offering,2.5098039215686274
1333,baseline,2.5
1334,collection,2.5
1335,dividend,2.5
1336,bank,2.5
1337,september,2.4941176470588236
1338,granted,2.4814814814814814
1339,obtain,2.4782608695652173
1340,testing,2.4782608695652173
1341,applicable,2.466666666666667
1342,facility,2.4657534246575343
1343,annual,2.4634146341463414
1344,revised,2.4545454545454546
1345,approval,2.453488372093023
1346,supply,2.45
1347,equity,2.449275362318841
1348,letter,2.4444444444444446
1349,primarily,2.4411764705882355
1350,patent,2.4375
1351,issued,2.4326923076923075
1352,public,2.4318181818181817
1353,average,2.4285714285714284
1354,commencement,2.4285714285714284
1355,application,2.4242424242424243
1356,future,2.4029850746268657
1357,production,2.4
1358,stock,2.3923444976076556
1359,credit,2.375
1360,based,2.364864864864865
1361,fee,2.357142857142857
1362,owned,2.357142857142857
1363,total,2.3529411764705883
1364,net,2.3506493506493507
1365,balance,2.3469387755102042
1366,cease,2.3333333333333335
1367,derived,2.3157894736842106
1368,regulatory,2.3125
1369,financing,2.3125
1370,provided,2.3076923076923075
1371,financial,2.3063063063063063
1372,reduce,2.3043478260869565
1373,pursuant,2.303030303030303
1374,immunodeficiency,2.3
1375,june,2.2904761904761903
1376,including,2.287671232876712
1377,rent,2.2857142857142856
1378,additional,2.2785714285714285
1379,title transfer,2.2765151515151514
1380,debt,2.2764227642276422
1381,manufacturer,2.272727272727273
1382,study,2.2666666666666666
1383,product,2.264705882352941
1384,payment,2.2641509433962264
1385,arrangement,2.260869565217391
1386,equal,2.25
1387,exercisable,2.25
1388,negative,2.25
1389,industry,2.25
1390,liquidity,2.25
1391,antibody,2.25
1392,prior,2.240740740740741
1393,activity,2.2325581395348837
1394,party,2.232142857142857
1395,principal,2.2280701754385963
1396,grant,2.225
1397,adma,2.2243589743589745
1398,funded,2.2222222222222223
1399,period,2.2216981132075473
1400,accounting,2.21875
1401,requirement,2.2142857142857144
1402,cash,2.2061855670103094
1403,borrowed,2.2
1404,officer,2.2
1405,location,2.2
1406,modification,2.2
1407,related,2.194244604316547
1408,level,2.1923076923076925
1409,unaudited,2.1875
1410,forfeiture,2.185185185185185
1411,service,2.183333333333333
1412,development,2.1791044776119404
1413,indebtedness,2.1739130434782608
1414,process,2.1714285714285713
1415,rsv,2.1707317073170733
1416,manufacturing,2.1702127659574466
1417,continuing,2.1666666666666665
1418,includes,2.161290322580645
1419,consisting,2.1578947368421053
1420,diluted,2.1538461538461537
1421,anticipated,2.15
1422,loan,2.1464646464646466
1423,storage,2.142857142857143
1424,normal,2.1379310344827585
1425,property,2.1363636363636362
1426,march,2.134831460674157
1427,impairment,2.1333333333333333
1428,contract,2.127659574468085
1429,option,2.12396694214876
1430,permitted,2.121212121212121
1431,igg,2.111111111111111
1432,percentage,2.103448275862069
1433,capital,2.1016949152542375
1434,transaction,2.097560975609756
1435,quantity,2.090909090909091
1436,receiving,2.090909090909091
1437,issue,2.085714285714286
1438,depending,2.0833333333333335
1439,method,2.076923076923077
1440,approximately,2.0760869565217392
1441,interim,2.0754716981132075
1442,lender,2.074074074074074
1443,agreed,2.0714285714285716
1444,license,2.0655737704918034
1445,administrative,2.0625
1446,rate,2.057142857142857
1447,revenue,2.055084745762712
1448,agreement,2.0530973451327434
1449,virus,2.0526315789473686
1450,year,2.0489510489510487
1451,current,2.0246913580246915
1452,disclosure,2.020408163265306
1453,organization,2.0
1454,information,2.0
1455,calculated,2.0
1456,tranche,2.0
1457,factor,2.0
1458,test,2.0
1459,wage,2.0
1460,earnings,2.0
1461,measurement,2.0
1462,measured,2.0
1463,vesting,2.0
1464,paid,2.0
1465,operated,2.0
1466,response,2.0
1467,undertaken,2.0
1468,warrant,1.989010989010989
1469,account,1.9838709677419355
1470,funding,1.9795918367346939
1471,amount,1.9789473684210526
1472,earlier,1.96875
1473,number,1.9642857142857142
1474,discount,1.9615384615384615
1475,data,1.9565217391304348
1476,lead,1.9523809523809523
1477,safety,1.9523809523809523
1478,attributable,1.9454545454545455
1479,securities,1.9411764705882353
1480,liability,1.9411764705882353
1481,term,1.9391304347826086
1482,goodwill,1.9375
1483,interest,1.935897435897436
1484,expense,1.93
1485,recognize,1.9285714285714286
1486,resubmission,1.9230769230769231
1487,position,1.9230769230769231
1488,obligation,1.9193548387096775
1489,pidd,1.9166666666666667
1490,requires,1.911764705882353
1491,asu,1.911764705882353
1492,underlying,1.9090909090909092
1493,prevent,1.9090909090909092
1494,recorded,1.9090909090909092
1495,basis,1.9090909090909092
1496,offset,1.9047619047619047
1497,corporate,1.903225806451613
1498,expansion,1.9
1499,gha,1.9
1500,selling,1.8888888888888888
1501,blood,1.8888888888888888
1502,included,1.8846153846153846
1503,commercialization,1.8837209302325582
1504,management,1.8775510204081634
1505,cost,1.875
1506,fold,1.875
1507,statement,1.874015748031496
1508,exercise,1.868421052631579
1509,volatility,1.8666666666666667
1510,expected,1.8611111111111112
1511,prepayment,1.8493150684931507
1512,received,1.849056603773585
1513,shipment,1.8461538461538463
1514,fda,1.8404907975460123
1515,aggregate,1.84
1516,market,1.8363636363636364
1517,biotest,1.834710743801653
1518,reason,1.8333333333333333
1519,estimated,1.8333333333333333
1520,judgment,1.8333333333333333
1521,efficacy,1.8333333333333333
1522,bpc,1.826086956521739
1523,stockholder,1.825
1524,conducted,1.8235294117647058
1525,prospectively,1.8181818181818181
1526,topic,1.8181818181818181
1527,amended,1.8055555555555556
1528,valuation,1.8
1529,necessarily,1.8
1530,treated,1.8
1531,present,1.8
1532,generated,1.8
1533,general,1.8
1534,btbu,1.8
1535,intermediate,1.8
1536,middle,1.8
1537,stated,1.8
1538,incurred,1.794871794871795
1539,condition,1.7878787878787878
1540,licensing,1.7878787878787878
1541,bivigam,1.7826086956521738
1542,notes,1.7820512820512822
1543,asset,1.7777777777777777
1544,business,1.7777777777777777
1545,vendor,1.7777777777777777
1546,hiring,1.7777777777777777
1547,million,1.7769230769230768
1548,assumption,1.7681159420289856
1549,exchange,1.7647058823529411
1550,covenant,1.7586206896551724
1551,georgia,1.7567567567567568
1552,december,1.755813953488372
1553,subsidiary,1.75
1554,made,1.75
1555,request,1.75
1556,marketing,1.75
1557,experience,1.75
1558,country,1.75
1559,grossman,1.75
1560,immediately,1.75
1561,substantially,1.75
1562,fill,1.75
1563,date,1.7470588235294118
1564,customer,1.7466666666666666
1565,note,1.7454545454545454
1566,loss,1.7411764705882353
1567,belief,1.7272727272727273
1568,segment,1.7272727272727273
1569,office,1.7272727272727273
1570,adopted,1.7272727272727273
1571,dependence,1.7142857142857142
1572,input,1.7142857142857142
1573,adversely,1.7142857142857142
1574,commercialize,1.7142857142857142
1575,planning,1.7142857142857142
1576,identified,1.7083333333333333
1577,report,1.696969696969697
1578,maturity,1.696969696969697
1579,principle,1.6923076923076923
1580,due,1.6923076923076923
1581,working,1.6923076923076923
1582,depreciation,1.6923076923076923
1583,completed,1.6911764705882353
1584,include,1.6785714285714286
1585,patient,1.6770833333333333
1586,filed,1.6666666666666667
1587,nature,1.6666666666666667
1588,conclusion,1.6666666666666667
1589,document,1.6666666666666667
1590,quality,1.6666666666666667
1591,provision,1.6666666666666667
1592,building,1.6666666666666667
1593,range,1.6666666666666667
1594,assist,1.6666666666666667
1595,collect,1.6666666666666667
1596,secure,1.6666666666666667
1597,billion,1.6666666666666667
1598,participate,1.6666666666666667
1599,step,1.6666666666666667
1600,package,1.6666666666666667
1601,acquisition,1.6538461538461537
1602,adoption,1.6538461538461537
1603,effect,1.6444444444444444
1604,adjustment,1.6444444444444444
1605,sell,1.6428571428571428
1606,inventory,1.6415094339622642
1607,manufacture,1.64
1608,differ,1.64
1609,reported,1.6363636363636365
1610,duration,1.6363636363636365
1611,risk,1.6338028169014085
1612,uncertainty,1.6333333333333333
1613,equipment,1.631578947368421
1614,delay,1.6296296296296295
1615,carrying,1.6285714285714286
1616,notice,1.625
1617,submission,1.625
1618,effective,1.6219512195121952
1619,presentation,1.6153846153846154
1620,milestone,1.6153846153846154
1621,apply,1.6153846153846154
1622,require,1.608695652173913
1623,occurs,1.6
1624,draw,1.6
1625,initiative,1.6
1626,deficiency,1.5862068965517242
1627,lsa,1.5819672131147542
1628,type,1.5714285714285714
1629,footnote,1.5714285714285714
1630,continued,1.5714285714285714
1631,impact,1.5692307692307692
1632,guidance,1.5636363636363637
1633,employee,1.5625
1634,affect,1.56
1635,accepted,1.5555555555555556
1636,obtained,1.5555555555555556
1637,analyze,1.5555555555555556
1638,good,1.5555555555555556
1639,february,1.55
1640,iii,1.55
1641,standard,1.5483870967741935
1642,claim,1.5454545454545454
1643,entered,1.542857142857143
1644,effort,1.5384615384615385
1645,intended,1.5333333333333334
1646,assessment,1.5294117647058822
1647,presented,1.5185185185185186
1648,lease,1.5166666666666666
1649,purchase,1.5147058823529411
1650,operates,1.5
1651,sufficient,1.5
1652,convertible,1.5
1653,lower,1.5
1654,represents,1.5
1655,failure,1.5
1656,reimburses,1.5
1657,accessing,1.5
1658,statements,1.5
1659,section,1.5
1660,implied,1.5
1661,strategy,1.5
1662,make,1.5
1663,outcome,1.5
1664,amortization,1.5
1665,acquirer,1.5
1666,america,1.5
1667,affirmatively,1.5
1668,round,1.5
1669,clarity,1.5
1670,buyer,1.5
1671,premises,1.5
1672,reflected,1.5
1673,interpretation,1.5
1674,sale,1.4948453608247423
1675,fund,1.488888888888889
1676,entity,1.4864864864864864
1677,timing,1.4827586206896552
1678,company,1.4819897084048028
1679,concern,1.4736842105263157
1680,limited,1.4705882352941178
1681,extension,1.4705882352941178
1682,classified,1.4666666666666666
1683,allowance,1.4545454545454546
1684,thing,1.4545454545454546
1685,income,1.4516129032258065
1686,event,1.4482758620689655
1687,adjusted,1.4444444444444444
1688,developing,1.4444444444444444
1689,fact,1.4444444444444444
1690,completion,1.4444444444444444
1691,dilution,1.4375
1692,infection,1.4324324324324325
1693,comprised,1.4285714285714286
1694,discontinue,1.4285714285714286
1695,evaluation,1.4285714285714286
1696,summary,1.4166666666666667
1697,evaluate,1.4137931034482758
1698,expenditure,1.4
1699,accelerated,1.4
1700,reasonable,1.4
1701,acquire,1.4
1702,person,1.4
1703,supplier,1.4
1704,results,1.3846153846153846
1705,hercules,1.380952380952381
1706,applied,1.368421052631579
1707,approved,1.3666666666666667
1708,occurrence,1.3636363636363635
1709,face,1.3636363636363635
1710,recognized,1.3617021276595744
1711,treatment,1.3571428571428572
1712,regulation,1.3571428571428572
1713,plan,1.3571428571428572
1714,hepatitis,1.3571428571428572
1715,closing,1.3529411764705883
1716,share,1.3416666666666666
1717,research,1.3333333333333333
1718,opinion,1.3333333333333333
1719,internal,1.3333333333333333
1720,achieved,1.3333333333333333
1721,computation,1.3333333333333333
1722,purpose,1.3333333333333333
1723,comparable,1.3333333333333333
1724,decline,1.3333333333333333
1725,managing,1.3333333333333333
1726,accounted,1.3333333333333333
1727,minimum,1.3333333333333333
1728,land,1.3333333333333333
1729,preliminary,1.3333333333333333
1730,ass,1.3333333333333333
1731,operation,1.3300970873786409
1732,oxford,1.328358208955224
1733,subject,1.3255813953488371
1734,day,1.3255813953488371
1735,estimate,1.318840579710145
1736,measure,1.3181818181818181
1737,amendment,1.3108108108108107
1738,suffer,1.3076923076923077
1739,occur,1.3076923076923077
1740,operations,1.3
1741,increase,1.3
1742,retrospectively,1.3
1743,expectation,1.2941176470588236
1744,seller,1.2941176470588236
1745,filing,1.2857142857142858
1746,begin,1.2857142857142858
1747,refinancing,1.2857142857142858
1748,entitled,1.2857142857142858
1749,order,1.2857142857142858
1750,perform,1.2857142857142858
1751,time,1.2771084337349397
1752,january,1.2727272727272727
1753,result,1.2692307692307692
1754,determine,1.263157894736842
1755,review,1.25
1756,commitments,1.25
1757,circumstance,1.25
1758,attributed,1.25
1759,compare,1.25
1760,reflects,1.25
1761,change,1.2432432432432432
1762,default,1.2307692307692308
1763,provide,1.2307692307692308
1764,intends,1.2222222222222223
1765,compliance,1.2222222222222223
1766,expire,1.2222222222222223
1767,november,1.2222222222222223
1768,customers,1.2222222222222223
1769,considered,1.2222222222222223
1770,fair,1.2210526315789474
1771,determined,1.2142857142857142
1772,anticipate,1.2142857142857142
1773,expensed,1.2105263157894737
1774,gaap,1.2105263157894737
1775,bla,1.2077922077922079
1776,required,1.2
1777,carried,1.2
1778,greater,1.2
1779,defined,1.2
1780,pathogen,1.2
1781,law,1.2
1782,form,1.1842105263157894
1783,portion,1.1818181818181819
1784,read,1.1818181818181819
1785,prepared,1.1818181818181819
1786,forward,1.1818181818181819
1787,issuance,1.1794871794871795
1788,engaged,1.1666666666666667
1789,discussion,1.1666666666666667
1790,amp,1.1666666666666667
1791,half,1.1538461538461537
1792,analysis,1.1538461538461537
1793,transfer,1.1515151515151516
1794,completing,1.1428571428571428
1795,secured,1.1428571428571428
1796,incorrect,1.1428571428571428
1797,repay,1.1333333333333333
1798,director,1.1333333333333333
1799,april,1.125
1800,title,1.125
1801,comparison,1.125
1802,manufactured,1.125
1803,food,1.1176470588235294
1804,meet,1.1176470588235294
1805,correction,1.1111111111111112
1806,matter,1.1111111111111112
1807,infusion,1.1111111111111112
1808,update,1.105263157894737
1809,expects,1.1
1810,august,1.1
1811,work,1.1
1812,anniversary,1.096774193548387
1813,extent,1.0909090909090908
1814,europe,1.0769230769230769
1815,connection,1.0769230769230769
1816,july,1.0588235294117647
1817,continue,1.0508474576271187
1818,benefit,1.0476190476190477
1819,decrease,1.04
1820,crl,1.0192307692307692
1821,quarter,1.019047619047619
1822,prevention,1.0
1823,inception,1.0
1824,october,1.0
1825,elect,1.0
1826,extend,1.0
1827,availability,1.0
1828,brings,1.0
1829,expect,1.0
1830,borrow,1.0
1831,incurrence,1.0
1832,restrict,1.0
1833,scope,1.0
1834,eliminate,1.0
1835,dependent,1.0
1836,ability,1.0
1837,assurance,1.0
1838,competitor,1.0
1839,consolidation,1.0
1840,eliminated,1.0
1841,conjunction,1.0
1842,sec,1.0
1843,accordance,1.0
1844,rule,1.0
1845,condensed,1.0
1846,resale,1.0
1847,recast,1.0
1848,conform,1.0
1849,delivery,1.0
1850,obligated,1.0
1851,pay,1.0
1852,amortized,1.0
1853,preparation,1.0
1854,determination,1.0
1855,computed,1.0
1856,excluded,1.0
1857,refinanced,1.0
1858,sum,1.0
1859,accrue,1.0
1860,addition,1.0
1861,itsfunding,1.0
1862,anniversarythrough,1.0
1863,merger,1.0
1864,solely,1.0
1865,qualified,1.0
1866,execution,1.0
1867,observe,1.0
1868,case,1.0
1869,cured,1.0
1870,viii,1.0
1871,attached,1.0
1872,taking,1.0
1873,possession,1.0
1874,prepaying,1.0
1875,extinguishment,1.0
1876,sold,1.0
1877,file,1.0
1878,estimating,1.0
1879,experienced,1.0
1880,established,1.0
1881,arise,1.0
1882,vest,1.0
1883,landlord,1.0
1884,insignificant,1.0
1885,member,1.0
1886,codm,1.0
1887,president,1.0
1888,shown,1.0
1889,part,1.0
1890,cite,1.0
1891,resolved,1.0
1892,brought,1.0
1893,labeled,1.0
1894,ending,1.0
1895,modified,1.0
1896,mandatory,1.0
1897,alter,1.0
1898,drawdown,1.0
1899,board,1.0
1900,directors,1.0
1901,meaning,1.0
1902,prediction,1.0
1903,forecast,1.0
1904,variation,1.0
1905,absence,1.0
1906,enable,1.0
1907,intend,1.0
1908,caution,1.0
1909,relying,1.0
1910,guarantee,1.0
1911,satisfaction,1.0
1912,build,1.0
1913,success,1.0
1914,timeframe,1.0
1915,labeling,1.0
1916,achievement,1.0
1917,acceptability,1.0
1918,comparability,1.0
1919,respect,1.0
1920,susceptible,1.0
1921,distributing,1.0
1922,profitable,1.0
1923,speak,1.0
1924,undertake,1.0
1925,achieve,1.0
1926,objective,1.0
1927,affected,1.0
1928,manage,1.0
1929,caused,1.0
1930,approve,1.0
1931,permit,1.0
1932,proceed,1.0
1933,enter,1.0
1934,unable,1.0
1935,cautioned,1.0
1936,prove,1.0
1937,caring,1.0
1938,cytomegalovirus,1.0
1939,addressing,1.0
1940,deficient,1.0
1941,hereditary,1.0
1942,age,1.0
1943,vulnerable,1.0
1944,cell,1.0
1945,body,1.0
1946,bacteria,1.0
1947,follow,1.0
1948,fifty,1.0
1949,enrolled,1.0
1950,reduction,1.0
1951,incidence,1.0
1952,pharmacokinetic,1.0
1953,sbi,1.0
1954,symptom,1.0
1955,child,1.0
1956,death,1.0
1957,zealand,1.0
1958,compared,1.0
1959,placebo,1.0
1960,observed,1.0
1961,administered,1.0
1962,compassionate,1.0
1963,treating,1.0
1964,onset,1.0
1965,diagnosis,1.0
1966,tolerated,1.0
1967,conference,1.0
1968,hire,1.0
1969,network,1.0
1970,uspto,1.0
1971,methods,1.0
1972,extends,1.0
1973,blending,1.0
1974,standardization,1.0
1975,garner,1.0
1976,liter,1.0
1977,locationswhere,1.0
1978,retain,1.0
1979,costly,1.0
1980,probability,1.0
1981,variety,1.0
1982,end,1.0
1983,relates,1.0
1984,remainder,1.0
1985,write,1.0
1986,repayment,1.0
1987,computer,1.0
1988,ipo,1.0
1989,interaction,1.0
1990,aggressively,1.0
1991,execute,1.0
1992,predict,1.0
1993,certainty,1.0
1994,decide,1.0
1995,suffering,1.0
1996,lack,1.0
1997,severity,1.0
1998,evaluating,1.0
1999,changesto,1.0
2000,disclose,1.0
2001,simplifying,1.0
2002,context,1.0
2003,contracts,1.0
2004,retrospective,1.0
2005,estimates,1.0
2006,jumpstart,1.0
2007,advantage,1.0
2008,longer,1.0
2009,elected,1.0
2010,comply,1.0
2011,applies,1.0
2012,adopt,1.0
2013,base,1.0
2014,critical,1.0
2015,understanding,1.0
2016,award,1.0
2017,revalued,1.0
2018,utilized,1.0
2019,examining,1.0
2020,disposition,1.0
2021,collaborate,1.0
2022,address,1.0
2023,awaiting,1.0
2024,feedback,1.0
2025,agency,1.0
2026,timeline,1.0
2027,practicable,1.0
2028,improvements,1.0
2029,simplification,1.0
2030,aspect,1.0
2031,classification,1.0
2032,assessing,1.0
2033,uncertainties,1.0
2034,determining,1.0
2035,enhance,1.0
2036,consistency,1.0
2037,responsibility,1.0
2038,performing,1.0
2039,ifrss,1.0
2040,entry,1.0
2041,focus,1.0
2042,receipt,1.0
2043,deferring,1.0
2044,generation,1.0
2045,ifrs,1.0
2046,finisher,1.0
2047,remediate,1.0
2048,recoverability,1.0
2049,definition,1.0
2050,clarifies,1.0
2051,disposal,1.0
2052,screen,1.0
2053,contribute,1.0
2054,output,1.0
2055,evaluated,1.0
2056,adam,1.0
2057,assume,1.0
2058,signing,1.0
2059,deliver,1.0
2060,excess,1.0
2061,designate,1.0
2062,contributed,1.0
2063,mortgage,1.0
2064,earnest,1.0
2065,utilize,1.0
2066,expiration,1.0
2067,refers,1.0
2068,controls,1.0
2069,cmc,1.0
2070,remediating,1.0
2071,relaunch,1.0
2072,anticipation,1.0
2073,increasing,1.0
2074,hour,1.0
2075,redemption,1.0
2076,buildout,1.0
2077,forced,1.0
2078,exempt,1.0
2079,certified,1.0
2080,rich,1.0
2081,refile,1.0
2082,structuring,1.0
2083,found,1.0
2084,occurred,1.0
2085,amends,1.0
2086,remove,1.0
2087,comparing,1.0
2088,exceed,1.0
2089,outline,1.0
2090,supersedes,1.0
2091,applying,1.0
2092,clarify,1.0
2093,clarification,1.0
2094,assigned,1.0
2095,adolescent,1.0
2096,hypotension,1.0
2097,hepatic,1.0
2098,chargebacks,1.0
2099,inclusion,1.0
